Table 2.

Seventy-three de novo malignancies diagnosed in 64 patients after liver transplantation for primary sclerosing cholangitis (excluding nonmelanoma skin cancer)

Organ	N (%)	Tumor type	Time to cancer in years Median(range)	Outcome
Skin (8.2%)	5 (6.8%)	Melanoma	4.88 (4.16–13.8)	All survived
Hematology (30.1%)	18 (24.7%)	Lymphoproliferative disease (PTLD)	5.24 (0.19–30)	3 died of refractory/recurrent disease 6 were positive for EBV, 9 were negative and 3 were unknown 1 developed CNS lymphoma
	2 (2.7%)	Myelodysplastic syndrome (MDS)	13.25 (9.80–16.70)	2 died of acute myeloid leukemia (AML) on MDS
	2 (2.7%)	Hodgkin’s disease	5.34 (0.57–10.10)	both died of cancer and complications
Solid-organ (63.0%)	11 (15.1%)	Renal Cell Cancer	11.7 (3.54–26.7)	All survived
	11 (15.1%)	Colorectal Cancer	6.17 (0.31–22.9)	9 colon cancer and 2 rectal cancer 5 died of metastatic disease
	7 (9.6%)	Prostate adenocarcinoma	6.24 (1.93–22.5)	All survived
	5 (6.8%)	Pancreatic adenocarcinoma	7.72 (5.22–10.0)	5 died of metastatic disease
	5 (6.8%)	Breast Cancer	3.93 (2.12–12.8)	4/5 survived (1 who died from Hodgkin’s disease)
	4 (5.5%)	Intrahepatic cholangiocarcinoma (de novo)	18.05 (5.17–28.5)	All had Roux-en-Y hepaticojejunostomy anastomosis PSC recurred in all patients All died of metastatic disease
	1 (1.4%)	Ovarian Cancer	22.4	died of metastatic disease
	1 (1.4%)	Endometrial Cancer	5.65	died of metastatic disease
	1 (1.4%)	Vulvar Cancer	22.1	survived